Through comprehensive screening, we demonstrated that the mutant IDH1 inhibitor ivosidenib significantly enhances the sensitivity of BRCA1/2-proficient breast and ovarian cancer cells to PARP inhibitors (PARPi). Here, PARP1 is linked to ovarian cancer.